Table 3. Univariate and multivariate analyses of clinical variables and quantitative metabolic parameters for disease-free survival.

Variables	Univariate analysis			Multivariate analysis
	HR	95% CI	P	HR	95% CI	P
Age (years) <45 vs. ≥45	1.030	0.6–4.2	0.310
Primary tumor SUVmax >12.3 vs. ≤12.3	0.673	0.5–4.0	0.412
Primary tumor MTV >63.7 cm3 vs. ≤63.7 cm3	2.172	0.8–5.6	0.141
Primary tumor TLG >411.9 vs. ≤411.9	2.294	0.8–5.8	0.130
Nodal SUVmax >4.7 vs. ≤4.7	7.592	1.8–34.8	0.006	4.158	1.1–22.7	0.041
Nodal MTV >10.3 cm3 vs. ≤10.3 cm3	6.015	1.3–9.2	0.014
Nodal TLG >32.9 vs. ≤32.9	6.266	1.3–9.4	0.012
FIGO stage >IIB vs. IIB	1.695	0.7–5.2	0.193
Tumor size ≥4 cm vs. <4 cm	0.811	0.5–5.1	0.368
Paraaortic node metastases	5.393	1.2–8.5	0.020
Post-treatment response PR or PD vs. CR	13.289	2.4–17.0	<0.001	7.162	1.5–11.3	0.007

SUVmax = maximum standardized uptake value; MTV = whole-body metabolic tumor volume; TLG = total lesion glycolysis; FIGO = International Federation of Gynecology and Obstetrics; CR = complete response; PR = partial response; PD = progressive disease; HR = hazard ratio; CI = confidence interval.